CCN2 and cardiac hypertrophy: 400 mg/kg of valproic acid improved congestive heart failure, cardiac hypertrophy, and fibrosis by inhibiting the manifestation of HDAC8, HDAC2, TGF-β1 (transforming growth factor-β1), and CTGF (connective tissue growth factor) (Li et al., 2017).